Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label management strategies after response to etanercept in plaque psoriasis
2008-004439-39Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of etanercept in plaque psoriasis and psoriasis (2 arms), sponsored by Pfizer. Primary endpoint: Average 52-week Physician's Global Assessment (PGA). Started Sep 2009; status: completed.
02
Drugs
etanercept
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2008-004439-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004439-39.